Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Chen, Chang, Zhang, Yi, Huang, Jianying, Yin, Ping, Cheng, Zhenshun, Wu, Jianyuan, Chen, Song, Zhang, Yongxi +6 more·2020·Frontiers in Pharmacology
DOI 10.1101/2020.03.17.20037432

Cited by (675)

Items 601–675 of 675

  1. Managing Rheumatic Diseases in COVID-19
    Sadettin Uslu · 2022 · The Anatolian Journal of General Medical Research
  2. Hepatotoxicity in Patients Using Favipiravir for COVID-19: A Retrospective Study
    Sinem Akkaya Işık, Burak Sarıkaya · 2022 · Hamidiye Medical Journal
  3. Endurance of COVID 19 in wastewater, natural prescription and antiviral medication for the analysis of COVID 19 and its effects on the development of new antiseptic strategies
    R. Sivaranjanee, P. S. Kumar, G. Rangasamy · 2022 · Total Environment Research Themes
  4. Clinical utility of repurposing a short course of hepatitis C drugs for COVID19. A randomized controlled study
    M. Yakoot, B. Eysa, Essam Gouda et al. · 2022 · medRxiv
  5. Drug combination therapies for SARS-CoV-2 (COVID-19) treatment
    Genevieve Dable-Tupas, Cecile Melisse P. Derecho · 2022 · Elsevier eBooks
  6. Current therapeutic strategies to combat coronavirus disease 2019
    Abhishek Pandey · 2022 · Elsevier eBooks
  7. Therapeutic Interventions Implemented During the First Year of the COVID-19 Pandemic: A Systematic Review of Evidence
    Özen Aşut, Şanda Çalı · 2022 · Cyprus Journal of Medical Sciences
  8. Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with Non-critical COVID-19: A Single-center, Retrospective, Propensity Score-matched Study
    O. A. Uyaroğlu, M. Ç. Sönmezer, Gülçin Telli Dizman · 2022 · Acta medica
  9. Safety of Favipiravir for Treatment of COVID-19: Latest Systematic Review
    Rizki Oktarini, Ratika Rahmasari, Rani Sauriasari · 2022 · Jurnal respirologi Indonesia
  10. Coronavirus disease 2019 in Saudi Arabia: A nationwide real-world characterization study
    Khalidah A. Alenzi, Wafi F. Albalawi, Tahani S. Alanazi · 2022 · Saudi Pharmaceutical Journal
  11. Home isolation, monitoring and follow-up as a management approach for mild to moderate COVID-19: a prospective observational study
    Satish Chandra Kilaru, Prasad Eswara Chelluri, Nagender Prasad Chenimilla, Ramya Krishna, Pradeep kumar Dasari, Kashif Momim, Umair Syed, Kishan Rao Thummanapally, Narasinga Reddy Toutireddy, Ramesh Tippani · 2022 · International Journal of Research in Medical Sciences
  12. Use of favipiravir against Covid-19: A Review
    E. Syed, Mati Ullah, Ataul Mustafa · 2022 · Pakistan BioMedical Journal
  13. Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2
    Mehmet Altay Ünal, Ömür Beşbinar, Hasan Nazır, Gökçe Yağmur Summak, Fatma Bayrakdar, Lucia Gemma Delogu, Tambay Taskin, Síbel A. Özkan, Kamil Can Akçalı, Açelya Yılmazer · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  14. Possible Mechanisms of Drugs Used in the Treatment of COVID-19: A Pharmacological Perspective
    Ravindra Babu Pingili, Tanvija Kodali, Naveen Babu Kilaru, Vijaya ramu Dirisala, Siva Reddy Challa, Akhila Kondru, Sirisha Koppula, Sravani Melike, Vyshnavi Toleti, Vara Prasad Saka · 2022 · Journal of Pharmaceutical Research International
  15. Does Favipiravir Reduce Mortality in Patients with COVID-19 ARDS and Severe Pneumonia?
    Khin Zar Li Aung, Rabia Yılmaz, Ezgi Güngördü, Sinan Aşar, Yasemin Tekdöş Şeker · 2021 · Türk yoğun bakım derneği dergisi/Türk yoğun bakım dergisi
  16. Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study
    Rand A. Alattar, Shiema Abdalla, Tasneem A. K. Abdallah et al. · 2021 · medRxiv
  17. A Narrative Review of Existing Options for COVID-19-Specific Treatments
    Wasey Ali Yadullahi Mir, Abdul Hasan Siddiqui, Gautam Kishore Valecha, Shawn Patel, Fatima Ayub, Riddhi Upadhyay, Sana Alhajri, Suman Gaire, Dhan Bahadur Shrestha · 2021 · Advances in Virology
  18. O uso da Hidroxicloroquina no decorrer da pandemia da COVID-19: um estudo de revisão bibliográfica
    Amanda Brito da Silva, Beatriz Bonfadini de Sá Galbraith, Camila Lopes Rieke Borges, Daniel Pereira de Rezende Sarmento Costa, Danilo Bines, Gabriela Carreiro Kubitschek Lopes, Hannah B. V. Bekierman, Helena F. Bruzzi, Júlia Moraes de Andrade Seabra, Julia Vieira Santos et al. · 2021 · Research Society and Development
  19. 2019 novel Coronavirus: current knowledge, cardiovascular implications and management
    Luigi Cappannoli, Roberto Scacciavillani, Giulia Iannaccone, Gianluca Anastasia, Federico Di Giusto, Filippo Crea · 2021 · Minerva Cardiology and Angiology
  20. First experience of using favipiravir in the first healthcare worker patient with moderate case of Coronavirus Disease 2019 (COVID-19) at Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia: a case report
    P. A. Sitompul, N. Mariana, A. Rusli · 2021 · Health Science Journal of Indonesia
  21. Effectiveness of Antiviral Drugs as Covid-19 Therapy
    Adelia Firandi, D. Hasmono · 2021 · Journal of Tropical Pharmacy and Chemistry
  22. Therapeutic approaches to tackle COVID-19: An overview
    Princy Louis Palatty, Rosme David, Belinda Mangalath Philip, Clint Sunny, J Mamatha, S Vanditha, Deepthi Mary George · 2021 · Indian Journal of Pharmacy and Pharmacology
  23. Mecanismos de acción de agentes propuestos para el tratamiento farmacológico específico de la infección por SARS-CoV-2
    R. Bastián Abarca, M. Pavan Dadlani, I. Jorge Widerstrom · 2021 · Revista chilena de enfermedades respiratorias
  24. COVID-19 TEDAVİSİNDE İLAÇ-İLAÇ ETKİLEŞİMLERİNİN FARMAKOKİNETİK AÇIDAN DEĞERLENDİRİLMESİ
    Nuran COŞKUN, Özge Lalegül‐Ülker · 2021 · Ankara Universitesi Eczacilik Fakultesi Dergisi
  25. FAVIPIRAVIR AND DEXAMETHASONE IN MANAGEMENT OF SARS-COV2 INFECTION
    Muzamil Latief, O. Shafi, Z. Hassan · 2021 · International Journal of Medicine and Medical Research
  26. Recomendaciones para el estudio y manejo farmacológico en pacientes adultos con sospecha de infección por SARS-CoV-2 (COVID-19) Documento conjunto de Sociedad Chilena de Infectología, Sociedad Chilena de Medicina Intensiva y Sociedad Chilena de Enfermedades Respiratorias. Octubre 2020
    Jorge Pérez, R. Rosales, F. Bernal et al. · 2021 · Revista chilena de enfermedades respiratorias
  27. FACTORS AFFECTING INTENSIVE CARE AND MORTALITY IN SARS-CoV 2019 HOSPITAL PATIENTS
    G. Uzan, Bedriye Kar, E. Karakas · 2021 · International journal of scientific research
  28. A Systematic Review of the Clinical Studies in Humans for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: Clinical Manifestation, Diagnosis and Clinical Trials
    G. Belachew, Paramesh Hanumanthaiah, Fekede Meshesha Namo · 2021 · Journal of Pharmaceutical Research International
  29. COVID-19: A need for new rather than repurposed antiviral drugs
    Dory Kovacs, Chris Davis, P. Cannon et al. · 2021 · bioRxiv
  30. A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations
    S. Fateh, S. T. Fateh, E. Salehi · 2021 · medRxiv
  31. COVID-19 treatments | A glance at the most recent reported drugs, which may close to the operational phase
    Sirvan Abbasbeigi · 2021
  32. Interactions between Cytokines and Drugs in COVID-19 Potential Interactions between Increased Cytokines in COVID-19 and Drugs used to Treat COVID-19
    Tülün Öztürk, Tuğba Çavuşoğlu, Canet İncir, Yeşim Tunçok · 2021 · Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
  33. Promising Investigational Therapeutic Drugs for the Treatment of COVID-19: A Review
    A. Bhushan, Anuradha Vummenthala · 2021
  34. The Pathophysiology of Repurposed Antiviral Drugs for treatment of COVID-19 Infection
    Adnan Haider, Muhammad Qaiser Faheem, Sayed Babar Jamal, Muhammad Naeem, Atif Ali Khan Khalil, Raees Khan, Fazli Subhan · 2020 · Life and Science
  35. The Pharmaceuticals Using for COVID-19 Patients and in Silico Natural Product Studies about COVID-19
    Sibel Avunduk · 2020 · Biomedical Journal of Scientific & Technical Research
  36. A review of pharmacotherapy for coronavirus disease 2019 (COVID-19)
    E. Saeedi, M. Soodmand, Mahdi Mashhadi Akbar Boojar · 2020
  37. Hematological and biochemical characteristics of COVID-19 non-survivors: a meta- and network analysis
    Rasoul Kowsar, Khaled Sadeghi, Sayed Farshad Kateb, Elham Bonakdar, Amir Hossein Mahdavi, Amir Mohammad Rahimi, Magdalena Sr · 2020 · Research Square
  38. Biological features of SARS-CoV-2 and current approaches to antiviral therapy and vaccination
    Snježana Židovec Lepej, Petra Korać, Dijana Škorić, Margarita Batović, Paula Gršković, Valerija Begić, Suzana Harabajsa, Leona Radmanić, Petra Šimičić · 2020 · Molecular and experimental biology in medicine
  39. Antiviral Treatment for COVID-19: A Systematic Review
    F. A. Arias, Pier Teran-Chavez, Alessandra Maggi-Panato · 2020
  40. COVID-2019: Una revisión de la nueva crisis pandémica
    Ricardo R. Contreras · 2020 · NOVASINERGIA REVISTA DIGITAL DE CIENCIA, INGENIERÍA Y TECNOLOGÍA
  41. Updates on the Current Antivirals Therapy for the COVID-19 Pandemic: A Mini-Review
    Mahmoud Radwan, Aymen Elsous, Rizwana Hussain · 2020 · American Journal of Laboratory Medicine
  42. Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysis
    Yi Li, Wei He · 2020 · medRxiv
  43. COVID-19 RECENT UPDATES AND THERAPEUTIC HOPE
    V. Mahajan, Rahul S. Taywade, J. Choudhary · 2020
  44. The Impact of Current COVID-19 Therapeutics on Patients’ Clinical Improvements Based on Disease Severity; A Systematic Review.:
    H. Talaie, M. Nazari, S. M. Hosseini · 2020
  45. Genetic determinants of COVID-19 drug efficacy revealed by genome-wide CRISPR screens
    Wei Jiang, Ailing Yang, Jing Ma et al. · 2020
  46. An Unexpected Diagnosis of COVID-19 in a Trauma Patient
    Y. S. Akdeniz, B. Tutar, S. Biberoğlu · 2020 · Phoenix Medical Journal
  47. Эффективность и безопасность применения фавипиравира при COVID-19 легкого и среднетяжелого течения: результаты рандомизированного исследования
    Татьяна Руженцова, Павел Чухляев, Дарья Хавкина et al. · 2020
  48. Repurposable Drug Candidates are Potential Therapeutic Target against Global SARS-CoV-2 Crisis
    Md. Siddikur Rahman, Fahmida Begum Mina, Sabuj Das, Mutasim Billah, Sumon Karmakar, Alam Khan, Sharmin Akhtar, Uzzal Kumar Acharjee, Md. Faruk Hasan · 2020 · Journal of Drug Delivery and Therapeutics
  49. Rationale and prognosis of repurposed drugs with risk stratification of COVID-19 patients requiring Oxygen supplementation: A systematic review and meta-analysis
    Esther Jebarani Elangovan, Vanitha Shyamili Kumar, Adhithyan Kathiravan · 2020 · medRxiv
  50. Therapeutic Approach to Coronavirus Disease
    Caroline A Der-Nigoghossian, Alana Ciolek, Taylor Chuich · 2020 · Springer eBooks
  51. Pharmacological and Nonpharmacological Studies on Coronavirus Disease 2019: A Mini-review of the Recent Evidence
    A. Bahmani, Mehdi Hoorang, S. Hosseini · 2020 · Journal of Research in Pharmacy Practice
  52. Association factors with severe cases and antiviral drug assessment in patients with COVID-19
    X. Gong, Xianfeng Guo, Shi-Wei Kang · 2020
  53. Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
    Thomas M. Hill, Mark R Baker, Lawrence Isherwood, Lennard Y. W. Lee · 2020 · medRxiv
  54. Overview of the status of the development of antiviral drugs for COVID-19
    Seung Yun Lee, Ji Hyup Kang, Hea Jin Kang, Sun Jin Hur · 2020 · Food and Life
  55. Can favipiravir help in coronavirus treatment?
    Shaik Ali Hassan, S. Bhateja, G. Arora · 2020
  56. Treatment of COVID-19: A review of emerging treatment
    C. Wanigatunge, D. Munidasa, W. Uluwattage · 2020 · Journal of the Ceylon College of Physicians
  57. As Drugs Assemble to Treat SARS-COV-2, Which Drug will Prove Efficacious : A Search for Suitable Drug or Vaccine to Manage COVID-19 Pandemic
    G. Jombo, AM Onoja, K. Adigun · 2020
  58. Efficacité et innocuité des agents antiviraux contre le SRAS-CoV-2, selon des données d’études sur la COVID-19 et d’autres infections virales aiguës : revue systématique et méta-analyse
    Wei Yong Liu, Pengxiang Zhou, Ken Chen, Zhikang Ye, Fang Liu, Xiaotong Li, Na He, Ziyang Wu, Qi Zhang, Xuepeng Gong et al. · 2020 · Canadian Medical Association Journal
  59. A literature review of drugs for the treatment of COVID-19
    Yuri N. Clement, Satish Jankie, Shalini Pooransingh, Diane Ignacio, Avril Reid, Shurla Sampson-Francis, Stanley Giddings, Harold R. Watson · 2020 · Caribbean Medical Journal
  60. COVID-19 Pandemic Simulation Studies on the Transmissibility
    Hyunjo Kim · 2020 · Cohesive Journal of Microbiology & Infectious Disease
  61. Uso de resúmenes de evidencia para informar el tratamiento farmacológico de personas con sospecha o diagnóstico de infección respiratoria por SARS CoV-2 / COVID-19
    Nancy Yomayusa González, Eduardo Low Padilla, Ilich Herbert De la Hoz Siegler et al. · 2020 · Revista Colombiana de Nefrología
  62. Comparison of the efficacy and safety of antiviral agents for COVID-19: a systematic review and meta-analysis
    Hong-Wei Peng, Li-Li Liu, Zhang-Ren Chen et al. · 2020 · Journal of Molecular and Clinical Medicine
  63. R
    E. Gugliandolo, A. Peritore, C. Piras · 2019 · Pangasinan Dictionary
  64. Treatment Options in CoViD19
    Umair Mallick · 2022 · Springer eBooks
  65. A Chemical Approach on Drugs that are Under Evaluation as Potential COVID-19’s Treatment
    Jéssica S. Pizzo, Patrícia D. S. Santos, Carlos Eduardo Rubio Senes, Victor Hugo Maldonado da Cruz, Patrícia Mendes de Souza, a Matheus C. de Castro, Oscar Oliveira Santos, Jesuí Vergílio Visentainer · 2022 · Revista Virtual de Química
  66. Repurposed drugs and their progression against COVID-19
    Heena Rani, S. Kaur, R. Sen · 2021
  67. El proceso de vacunación en México.
    J. Orellana-Centeno, R. G. Guerrero Sotelo · 2021 · Revista de la Asociación Dental Mexicana
  68. Covid-19: New Use of Therapeutics
    V. P. Kamboj · 2021 · Springer eBooks
  69. Coronavirus Disease 2019 in Kidney Transplant Recipients: Our Single Center Experiences
    S. Karadağ, Ramazan Uğur, E. Şam · 2021 · Grand Journal of Urology
  70. Global Efforts towards Potential Therapeutic Options for COVID-19
    P. Prajapati, R. Kumar, Santosh Kumar Prajapti · 2020
  71. [Drug treatment of coronavirus disease COVID-19: evidence exists?]
    S. Timerbulatov, M. V. Timerbulstov, E. Gainullina · 2020 · Khirurgiia
  72. A Simplified Approach to Covid-19 Disease in Adult Patients for General Practitioners
    Ehsan Y. Sabry · 2020 · International Journal of Respiratory and Pulmonary Medicine
  73. A study to assess the health literacy on knowledge regarding Nilavembu Kudineer and Kabasura Kudineer for immunity boosting of deadly viruses along with COVID -19 among adults in rural population
    S. Tamilselvi, S. Suganthi, Thamaraiselvi · 2020 · International Journal of Advance Research in Community Health Nursing
  74. Favipiravir: Promising Therapy for COVID-19
    Amitabha Das · 2020 · Journal of Tropical Diseases
  75. Response to Nigella sativa in Patients with Confirmed and Suspected COVID-19
    I. Fetian, Issa D Fitian, L. Villiger · heakthbook TIMES